Open AccessNon‐small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
Author(s) -
Huang Jing,
Wang Yiyin,
Zhai Yachao,
Wang Jin
Publication year - 2018
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12637
Subject(s) - osimertinib , gefitinib , medicine , exon , lung cancer , point mutation , cancer research , mutation , adenocarcinoma , tyrosine kinase , tyrosine kinase inhibitor , adenocarcinoma of the lung , acquired resistance , epidermal growth factor receptor , gene , oncology , cancer , erlotinib , genetics , biology , receptor
The most common EGFR mutations in non‐small cell lung cancer are exon 19 deletions and exon 21 point mutations, which are both sensitive to EGFR ‐tyrosine kinase inhibitors. However, rare EGFR mutations do exist and how these mutations respond to tyrosine kinase inhibitors is not well understood. A Chinese woman diagnosed with stage IV lung adenocarcinoma harbored a rare EGFR L747P (2239‐2240 TT > CC) mutation, and treatment with gefitinib and osimertinib failed to achieve the desired effect. Herein, possible correlations between gene analysis and the outcomes of subsequent treatment are discussed.